Handelsbanken Fonder AB Acquires 215,000 Shares of Structure Therapeutics Inc. (NASDAQ:GPCR)

Handelsbanken Fonder AB grew its holdings in shares of Structure Therapeutics Inc. (NASDAQ:GPCR - Free Report) by 130.3% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 380,000 shares of the company's stock after acquiring an additional 215,000 shares during the period. Handelsbanken Fonder AB owned about 0.66% of Structure Therapeutics worth $6,578,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Mariner LLC bought a new position in Structure Therapeutics during the 4th quarter worth $665,000. Invesco Ltd. raised its position in shares of Structure Therapeutics by 4.1% during the fourth quarter. Invesco Ltd. now owns 371,767 shares of the company's stock worth $10,082,000 after acquiring an additional 14,559 shares during the last quarter. Barclays PLC raised its position in shares of Structure Therapeutics by 42.6% during the fourth quarter. Barclays PLC now owns 115,671 shares of the company's stock worth $3,138,000 after acquiring an additional 34,533 shares during the last quarter. Foresite Capital Management VI LLC bought a new position in shares of Structure Therapeutics during the fourth quarter worth about $11,390,000. Finally, BNP Paribas Financial Markets bought a new position in Structure Therapeutics during the 4th quarter worth approximately $304,000. Institutional investors own 91.78% of the company's stock.

Wall Street Analysts Forecast Growth

Several research analysts have issued reports on GPCR shares. Citigroup initiated coverage on shares of Structure Therapeutics in a report on Friday, May 2nd. They set a "buy" rating and a $60.00 price target for the company. William Blair initiated coverage on shares of Structure Therapeutics in a research note on Friday, February 28th. They set an "outperform" rating for the company. Finally, HC Wainwright lowered their price objective on Structure Therapeutics from $80.00 to $75.00 and set a "buy" rating for the company in a research report on Monday, May 12th. Seven analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, Structure Therapeutics currently has an average rating of "Buy" and an average target price of $76.50.

Structure Therapeutics Stock Down 5.1%

GPCR traded down $1.11 during midday trading on Monday, hitting $20.57. The company had a trading volume of 599,945 shares, compared to its average volume of 852,329. Structure Therapeutics Inc. has a 52 week low of $13.22 and a 52 week high of $49.91. The company has a market capitalization of $1.18 billion, a price-to-earnings ratio of -27.80 and a beta of -1.87. The stock's 50 day moving average price is $22.77 and its 200 day moving average price is $24.46.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last issued its earnings results on Thursday, May 8th. The company reported ($0.27) EPS for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.03). Research analysts predict that Structure Therapeutics Inc. will post -0.82 EPS for the current year.

Structure Therapeutics Company Profile

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.